Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

3rd Microbiome Movement - Gut-Brain Axis Summit - December

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
georgejjl Member Profile
 
Followed By 80
Posts 11,861
Boards Moderated 0
Alias Born 04/08/04
160x600 placeholder
Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment o... GlobeNewswire Inc. - 11/14/2019 7:00:00 AM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome GlobeNewswire Inc. - 11/6/2019 7:00:00 AM
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease GlobeNewswire Inc. - 10/9/2019 7:00:00 AM
Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’... GlobeNewswire Inc. - 10/2/2019 7:00:00 AM
Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from th... GlobeNewswire Inc. - 9/27/2019 3:00:00 AM
Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire Inc. - 9/26/2019 7:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/23/2019 6:35:19 AM
Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire Inc. - 9/18/2019 7:00:00 AM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 9/17/2019 5:16:10 PM
CLS Holdings (CLSH) $1.15 Price Target - MASS Approval for Recreational License InvestorsHub NewsWire - 9/17/2019 7:17:00 AM
Withdrawal of Registration Statement (ammendment) (aw) Edgar (US Regulatory) - 9/16/2019 4:17:42 PM
Anavex Life Sciences Announces Preliminary Clinical Efficacy Data of its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patie... GlobeNewswire Inc. - 9/16/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/13/2019 5:11:08 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 9/13/2019 5:07:24 PM
Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 9/13/2019 5:02:44 PM
Anavex Life Sciences to Present at the Janney Healthcare Conference 2019 GlobeNewswire Inc. - 9/5/2019 7:00:00 AM
Anavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Ret... GlobeNewswire Inc. - 9/4/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/7/2019 4:07:28 PM
Anavex Life Sciences Reports Fiscal 2019 Third Quarter Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 8/7/2019 7:00:00 AM
Anavex Life Sciences to Announce Fiscal 2019 Third Quarter Financial Results on Wednesday, August 7th, 2019 GlobeNewswire Inc. - 8/2/2019 7:00:00 AM
Anavex Life Sciences Reports Recent Data Review by the Independent Data Safety Monitoring Board for its U.S. Phase 2 Clinical... GlobeNewswire Inc. - 7/31/2019 7:00:00 AM
Anavex Life Sciences Receives Positive Opinion for Orphan Designation from the European Medicines Agency for ANAVEX®2-73 for... GlobeNewswire Inc. - 7/29/2019 7:00:00 AM
Anavex Life Sciences Presents New Clinical Data Identifying Gut Microbiota Biomarkers Associated with Improved Clinical Respo... GlobeNewswire Inc. - 7/17/2019 11:45:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 7/16/2019 6:01:11 AM
Biotech Companies with Recent and Potential Near-Term Catalysts InvestorsHub NewsWire - 7/15/2019 8:15:00 AM
georgejjl   Friday, 10/11/19 08:27:02 PM
Re: None
Post # of 219968 
3rd Microbiome Movement - Gut-Brain Axis Summit - December



Quote:
As scientific researchers continue to investigate the complexities of the microbiome-gut brain communication highway, our mission for the 3rd Microbiome Movement - Gut-Brain Axis Summit is simple: Unite pioneering industry and academic researchers to establish the mechanistic pathways contributing to neurological disorder manifestation, overcome the scientific and translational challenges of working in the gut-brain setting and capitalize on this therapeutic opportunity.

Our conversations have highlighted that there are critical areas of basic science that need addressing including demonstrating the causality of microbiome gut-brain interactions, translating microbiome science into therapeutic or nutritional targets through pre-clinical models and harnessing clinical experience to inform in-human study design to accelerate product development.

If you're keen to make sense of microbiome gut-brain science and its potential applications in understanding neurological disorder etiology, identifying microbial biomarkers for patient stratification and development of innovative symptom management strategies, join your scientifically-driven peers from the pharmaceutical, nutritional and academic community to discover and clinically validate microbiome gut-brain axis pathways to transform treatment strategies for patients with neurological disorders.



Speakers: Christopher Missling, President And CEO, Anavex Life Sciences, David Donabedian, Co-Founder, CEO And Director, Axial Biotherapeutics, Melanie Maya Kaelberer, Post-Doctoral Fellow Bohorquez Lab, Duke University, Timothy Buie, Attending Gastroenterologist, Boston Children's Hospital, Michael Zasloff, Founder, CEO And Chairman, Enterin, Inc, Zain Kassam, Chief Medical Officer, Finch Therapeutics, Philip Strandwitz, CEO, Holobiome, Peter Nara, Chief Scientific Officer And Founder, Keystone Bio, Alessio Fasano, Professor And Director Mucosal Immunology And Biology, Research Center Massachusetts General Hospital, Stephen Skolnick, Research Technologist, Massachusetts Institute of Technology, Rishab Shyam, Executive Director, PureTech Health, Ali Keshavarzian, Professor And Gastroenterologist, Rush University Medical Center, Frank Middleton, Associate Professor, SUNY Upstate Medical University, Nader Yaghoubi, Co-Founder And CEO, Symbiotix Biotherapies Inc, Nicole Polinski, Senior Associate Director, Research Programs, The Michael J. Fox Foundation for Parkinson's Research, Valerie Taylor, Department Chair of Psychiatry And Scientist, University of Calgary And Hotchkiss Brain Institute, Jing Lu, Research Professional, University of Chicago, Ai-Ling Lin, Associate Professor, University of Kentucky

Date and Time:
On Tuesday December 03, 2019 at 8:00 am (ends Thursday December 05, 2019 at 5:00 pm)


Good luck and GOD bless,

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist